S
Sridhar K. Rabindran
Researcher at Bristol-Myers Squibb
Publications - 2
Citations - 1604
Sridhar K. Rabindran is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Lung cancer & Nivolumab. The author has an hindex of 2, co-authored 2 publications receiving 811 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D. Hellmann,Luis Paz-Ares,Reyes Bernabe Caro,B. Zurawski,Sang-We Kim,Enric Carcereny Costa,Keunchil Park,A. Alexandru,L. Lupinacci,Emmanuel de la Mora Jimenez,Hiroshi Sakai,Istvan Albert,Alain Vergnenegre,Solange Peters,Konstantinos N. Syrigos,Fabrice Barlesi,Martin Reck,Hossein Borghaei,Julie R. Brahmer,Kenneth J. O'Byrne,William J. Geese,Prabhu Bhagavatheeswaran,Sridhar K. Rabindran,Ravi S. Kasinathan,F. E. Nathan,Suresh S. Ramalingam +25 more
TL;DR: First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level.
Journal ArticleDOI
CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC.
Edward B. Garon,Niels Reinmuth,Lionel Falchero,Y. García,José Hureaux,Ira Gore,R. Harris,Paolo Bidoli,Editta Baldini,Silverio Ros,Eckart Laack,Paul Mitchell,Martin Wolf,Kenneth J. O'Byrne,Labib Zibdawi,Kevin Jao,David R. Spigel,Ang Li,Sridhar K. Rabindran,Eric Pichon +19 more
TL;DR: Nivo 480 mg Q4W showed similar efficacy and safety to 240 mg Q2W in pts with disease control on nivo, supporting the potential use of 480 mgQ4W as a more convenient dosing option for second-line NSCLC tx.